300142 沃森生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.6951.9691.5144.5508.295
总资产报酬率 ROA (%)0.4801.3270.9382.7125.023
投入资产回报率 ROIC (%)0.6171.8431.3914.1787.803

边际利润分析
销售毛利率 (%)68.78974.55879.69185.47488.018
营业利润率 (%)8.8027.7723.42614.92521.615
息税前利润/营业总收入 (%)9.8214.1214.51812.83519.807
净利润/营业总收入 (%)5.5075.1766.18112.43018.446

收益指标分析
经营活动净收益/利润总额(%)43.700187.298156.999160.534119.595
价值变动净收益/利润总额(%)-84.97819.392-50.576-38.004-17.519
营业外收支净额/利润总额(%)-6.103-13.14647.603-2.503-2.707

偿债能力分析
流动比率 (X)2.0742.3472.9822.7262.550
速动比率 (X)1.7652.0512.6642.4032.266
资产负债率 (%)30.17920.99521.84426.90128.340
带息债务/全部投入资本 (%)12.1261.6542.5894.1201.426
股东权益/带息债务 (%)687.0555,677.6193,603.8792,196.5716,535.940
股东权益/负债合计 (%)220.302340.186293.166222.946209.008
利息保障倍数 (X)6.439-1.500-2.236-7.437-15.997

营运能力分析
应收账款周转天数 (天)448.112339.054351.538292.173214.357
存货周转天数 (天)406.702388.159561.439611.627552.109